Maybe Cathie Wood and Wall Street are being too optimistic.Intellia Therapeutics (NTLA +2.89%), a small-cap biotech company, has some notable bulls. One of them is Cathie Wood, the CEO of Ark Invest. The innovation-focused investment firm has long held shares in Intellia, likely because of its work on potentially disruptive gene-editing technology.Intellia Therapeutics also has fans on Wall Street. The company's current average price target of $32.3 (according to Yahoo! Finance) implies a significant 131% u ...